ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry"

  • Abstract Number: 1218 • ACR Convergence 2022

    Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry

    Philip J Mease1, Alexis Ogdie2, Dimitrios Pappas3, George Reed4 and Joel Kremer5, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3CorEvitas, LLC, Waltham, MA, 4The Corrona Research Foundation and University of Massachusetts, Albany, NY, 5The Corrona Research Foundation, Delray Beach, FL

    Background/Purpose: Fibromyalgia (FM) occurs concomitantly with inflammatory rheumatic disease, including psoriatic arthritis (PsA), in up to 20% of patients and chronic widespread pain (CWP) in…
  • Abstract Number: 0258 • ACR Convergence 2022

    Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents

    Sascha Heckert1, Tjardo Maarseveen2, Emiel Marges2, Arvind Chopra3, David Vega Morales4, Riette Du Toit5, Annette van der Helm-van Mil6, Tom Huizinga2, CF Allaart2 and Sytske Anne Bergstra7, 1Leiden University Medical Centre, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Center for Rheumatic Diseases, Pune, Maharashtra, India, 4Hospital General de Zona 17, Instituto Mexicano del Seguro Social, Monterrey, Mexico, 5Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa, 6Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, 7LUMC, Leiden, Netherlands

    Background/Purpose: Interstitial lung disease (ILD) is a spectrum of inflammatory and fibrotic lung diseases, and can be associated with RA (RA-ILD). The reported prevalence in…
  • Abstract Number: 1308 • ACR Convergence 2022

    Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study

    Diala Alawneh1, Moustafa Younis2, Romesa Hassan1, Bashar Alzghoul2, Shiva Arami1, Tricha Shivas3, Mary McGowan3, Khaldoon Alawneh4, Christian Ascoli1 and Nadera Sweiss1, 1University of Illinois at Chicago, Chicago, IL, 2University of Florida, Gainesville, FL, 3Foundation for Sarcoidosis Research, Chicago, IL, 4Jordan University of Science and Technology, Irbid, Jordan

    Background/Purpose: Patients with sarcoidosis are at an increased risk of developing osteoporosis due to the active inflammatory state and chronic corticosteroid use. Proper dosing of…
  • Abstract Number: 0289 • ACR Convergence 2022

    Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry

    Song-Chou Hsieh1, Wei-Sheng Chen2, Jui-Chieh Hu3, Wan-Yu Sung4, Wen-Chan Tsai4, Hsiang-Cheng Chen5, Chung-Ming Huang6, Edward Kuo7, James Wee8, John Woolcott9 and Yi-Hsing Chen10, 1Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 2Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, 3Division of Allergy, Immunology and Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 4Department of Allergy, Immunology, and Rheumatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 5Division of Immunology, Rheumatology, and Allergy, Department of Medicine, Tri-Service General Hospital, Taipei, Taiwan, 6Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, 7Pfizer Ltd, Taipei, Taiwan, 8Pfizer Inc, Makati City, Philippines, 9Pfizer, Inc, Collegeville, PA, 10Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA and was approved under Taiwan's National Health Insurance (NHI) reimbursement system in…
  • Abstract Number: 1318 • ACR Convergence 2022

    Low-Dose Prednisolone (≤5 Mg/d) Is Not Associated with Deleterious Effects on Bone Mineral Density: Baseline Findings in a Cohort of Rheumatic Disease Patients with Prior Glucocorticoid Exposure

    Edgar Wiebe1, Dörte Huscher2, Desirée Schaumburg1, Andriko Palmowski1, Sandra Hermann1, Thomas Buttgereit3, Robert Biesen4, Gerd Burmester5, Yannick Palmowski6, Maarten Boers7, John Stone8, Christian Dejaco9 and Frank Buttgereit10, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 3Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 4Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 5Charité University Medicine Berlin, Berlin, Germany, 6Spine Department, Center for Musculoskeletal Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 7Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 8Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 9Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 10Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany

    Background/Purpose: Inflammatory rheumatic and musculoskeletal diseases (iRMD) are associated with increased systemic bone loss that is mediated by chronic inflammation, treatment with glucocorticoids (GC), and…
  • Abstract Number: 0290 • ACR Convergence 2022

    Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study)

    Kim Lauper1, Romain Aymon2, Denis Mongin2, Sytske Anne Bergstra3, Denis Choquette4, Catalin Codreanu5, Ori Elkayam6, Kimme Hyrich7, Florenzo Iannone8, Nevsun Inanc9, Lianne Kearsley-Fleet10, Tore K. kvien11, Eirik Kristianslund12, Burkhard Leeb13, Galina Lukina14, Dan Nordstrom15, Karel Pavelka16, Manuel Pombo-Suarez17, Ziga Rotar18, Maria José Santos19, Delphine Courvoisier20 and Axel Finckh21, 1Geneva University Hospitals, Genéve, Switzerland, 2Geneva University Hospitals, Geneva, Switzerland, 3LUMC, Leiden, Netherlands, 4Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, 5Center for Rheumatic Diseases, Bucharest, Romania, 6Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 7The University of Manchester, Manchester, United Kingdom, 8School of Medicine University of Bari, Bari, Italy, 9Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, 10Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, 11Diakonhjemmet Hospital, Oslo, Norway, 12Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway, 13Bioreg, Stockerau, Austria, 14Federal state budgetary scientific institution �Research Institute of rheumatology named after V. A. Nasonova�, Moscow, Russia, 15Helsinki University Hospital, Helsinki, Finland, 16Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, 17Hospital Clinico Universitario, Santiago de Compostela, Spain, 18University Medical Centre Ljubljana, Ljubljana, Slovenia, 19Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal, 20University Hospitals of Geneva, Geneva, Switzerland, 21Geneva University Hospital, Geneve - Vesenaz, Switzerland

    Background/Purpose: The "ORAL Surveillance" study1 suggests an increased risk of serious adverse events (AEs) with tofacitinib, a JAK-inhibitor (JAKi), compared to TNF-inhibitors (TNFi). Currently, there…
  • Abstract Number: 1380 • ACR Convergence 2022

    Development of Core and Expanded Datasets to Align Registries and Advance International Collaborative Research for Childhood-onset Systemic Lupus Erythematosus

    Rebecca Sadun1, Laura Lewandowski2, Alexandre Belot3, Eve Smith4 and Jennifer Cooper5, 1Duke University, Durham, NC, 2NIAMS, NIH, Bethesda, MD, 3Hospices Civils de Lyon, Collonges au mont d'or, France, 4University of Liverpool, Liverpool, United Kingdom, 5University of Colorado/Children's Hospital Colorado, Denver, CO

    Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) occurs in approximately 20% of all SLE cases. cSLE is has a worse prognosis than adult-onset SLE, often requiring…
  • Abstract Number: 0306 • ACR Convergence 2022

    Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry

    Gabriela Schmajuk1, Nevin Hammam2, Jing Li3, David Collier4, Greg Kricorian5 and Scott Stryker6, 1UCSF / SFVA, San Francisco, CA, 2Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, 3University of California, San Francisco, San Francisco, CA, 4Amgen Inc., Simi Valley, CA, 5Amgen, Inc., Thousand Oaks, CA, 6Amgen Inc., San Francisco, CA

    Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management…
  • Abstract Number: 1423 • ACR Convergence 2022

    Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting

    Regan Arendse1, Proton Rahman2, Philip Baer3, Derek Haaland4, Dalton Sholter5, Odalis Asin-Milan6, Meagan Rachich7, Emmanouil Rampakakis8, A. Marilise Marrache9 and Allen J. Lehman10, 1Community Rheumatology Care, Saskatoon, Canada, 2Memorial University, St. John's, NL, Canada, 3Baer Weinberg MPC, Scarborough, ON, Canada, 4The Waterside Clinic, Oro Medonte, ON, Canada, 5University of Alberta, Edmonton, AB, Canada, 6Janssen Canada, Laval, QC, Canada, 7Janssen Inc., Guelph, ON, Canada, 8McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 9Janssen Inc., Dollard-des-Ormeaux, QC, Canada, 10Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Golimumab (GLM), a tumor necrosis factor inhibitor (TNFi), has demonstrated efficacy and a favorable safety profile in inflammatory rheumatic diseases. Recent safety studies with…
  • Abstract Number: 0350 • ACR Convergence 2022

    Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus

    Vicente Aldasoro1, María Laiño1, Monica Enguita1, Santos Castañeda2, Javier Loricera3, Carmen Lasa-Teja4, Clara Moriano5, Vanesa Calvo Río6, Ivette Casafont-Solé7, Judit Font Urgelles7, Patricia Quiroga-Colina8, Samuel Hernandez9, Sergi Heredia10, A. Garcia-Aparicio11, Joaquin Maria Belzunegui Otano12, Aaron Fariña13, Francisco Javier Navarro Blasco14, Patricia Fanlo Mateo1, Adela Gallego15, Juan M Blanco Madrigal16, María Ángeles Matías17, Cilia Peralta18, Jordi Camins-Fàbregas19, Marcos Paulino20, Ana Urruticoechea21, Piter Jose Cossio Jimenez22, Miguel Medina Malone23, Eva Perez Pampin24, Rafaela Ortega-Castro25, Blanca varas de Dios26, Jose Ramon Lamua Riazuelo27 and Emilio Jose Giner28, 1Hospital Universitario de Navarra, Pamplona, Spain, 2Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 3Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Complejo Asistencial Universitario de León, León, Spain, 6Valdecilla Hospital, Santander, Spain, 7Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 8Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 9Hospital Son Llàtzer, Palma de Mallorca, Spain, 10Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despi, Spain, 11Hospital Universitario de Toledo, Toledo, Spain, 12Hospital Universitario de Donostia, Donostia-San Sebasti, Spain, 13Complejo Asistencial Universitario de Palencia, Palencia, Spain, 14Hospital General Universitario de Elche, Elche, Spain, 15Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 16Basurto University Hospital, Bilbao, Spain, 17Hospital Universitario Infanta Leonor, Madrid, Spain, 18Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 19Hospital General de Granollers, Granollers, Spain, 20Hospital General Universiario de Ciudad Real, Ciudad Real, Spain, 21Hospital Can Misses, Ibiza, Spain, 22Hospital Reina Sofia, Tudela, Spain, 23Hospital Calahorra, Calahorra, Spain, 24Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago, Cordoba, Spain, 25IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 26Santa Cristina Hospital, Madrid, Spain, 27Hospital Universitario del Henares, Madrid, Spain, 28Hospital Royo Villanova, Zaragoza, Spain

    Background/Purpose: To describe demographic characteristics, efficacy and safety of BLM since its approval in SLE patients in a real-world setting. Methods: Descriptive, retrospective, multicenter study…
  • Abstract Number: 1431 • ACR Convergence 2022

    Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis

    Karen E Hansen1, Mahta Mortezavi2, Edward Nagy3, Cunshan Wang4, Carol A Connell4, Zaher Radi5, Heather J Litman6, Giovanni Adami7 and Maurizio Rossini7, 1Rheumatology Division, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 2Pfizer Inc, New York, NY, 3Pfizer Ltd, Tadworth, United Kingdom, 4Pfizer Inc, Groton, CT, 5Pfizer Inc., Cambridge, MA, 6CorEvitas, LLC, Waltham, MA, 7Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy

    Background/Purpose: Preclinical data suggest that tofacitinib stimulates osteoblast function and would have a protective effect on bone health and fracture risk in RA.1 We report…
  • Abstract Number: 0422 • ACR Convergence 2022

    Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort

    Semih Gulle1, Ali Karakas1, Gercek Can2, Soner Senel3, Sedat Capar4, Huseyin ediz dalkilic5, Servet Akar6, Suleyman Serdar Koca7, Abdurrahman Tufan8, Ayten Yazici9, Sema Yilmaz10, Nevsun Inanc11, Merih Birlik1, Dilek Solmaz12, Ayse Cefle9, Berna Goker13, Servet Yolbas14, Niels Steen Krough15, Neslihan Yilmaz16, Sukran Erten17, Cemal Bes18, Ozgul Soysal19, Mehmet Akif Ozturk13, Seminur Haznedaroglu13, Sule Yavuz16, Haner Direskeneli20, Fatoş Onen21 and Ismail Sari22, 1Dokuz Eylul University School of Medicine Division of Rheumatology, Izmir, Turkey, 2Dokuz Eylul University School of Medicine Division of Rheumatology, Istanbul, Turkey, 3Erciyes University School of Medicine Division of Rheumatology, Kayseri, Turkey, 4Dokuz Eylul University Faculty of Science Department of Statistics, Izmir, Turkey, 5Uludag University School of Medicine Division of Rheumatology, Bursa, Turkey, 6Izmir Katip Celebi University School of Medicine, Izmir, Turkey, 7Firat University School of Medicine Division of Rheumatology, Elazıg, Turkey, 8Gazi University Medical Faculty Hospital, Istanbul, Turkey, 9Kocaeli University School of Medicine Division of Rheumatology, Kocaeli, Turkey, 10Selcuk University School of Medicine Division of Rheumatology, Konya, Turkey, 11Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, 12Kâtip Celebi University School of Medicine Division of Rheumatology, Izmir, Turkey, 13Gazi University School of Medicine Division of Rheumatology, Ankara, Turkey, 14Inonu University School of Medicine Division of Rheumatology, Malatya, Turkey, 15Zitelab Aps, Kopenhag, Denmark, 16Demiroglu Bilim University School of Medicine Division of Rheumatology, Istanbul, Turkey, 17Yildirim Beyazit University School of Medicine Division of Rheumatology, Ankara, Turkey, 18Basaksehir Cam and Sakura ospital, Division of Rheumatology, Istanbul, Turkey, 19Celal Bayar University, School of Medicine Division of Rheumatology, Manisa, Turkey, 20Marmara University School of Medicine Division of Rheumatology, Istanbul, Turkey, 21Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey, 22Dokuz Eylul University School of Medicine Division of Rheumatology, İzmir, Turkey

    Background/Purpose: In this study, we aimed to evaluate the results of secukinumab treatment in patients with Axial Spondyloarthritis (AxSpA) who were enrolled in the TURKBIO…
  • Abstract Number: 1522 • ACR Convergence 2022

    The Collaborative National Quality and Efficacy Registry for Scleroderma: Association of Medication Use on Gastrointestinal Tract Symptoms in Early Disease

    Sarah Luebker1, Tracy Frech1, Shervin Assassi2, Jessica Gordon3, Elana Bernstein4, Virginia Steen5, Ami Shah6, Laura Hummers7, Carrie Richardson8, Dinesh Khanna9, Flavia Castelino10, Lorinda Chung11, Faye Hant12, Vicki Shanmugam13, John VanBuren14, Jessica Alvey14, Monica Harding14, Luke Evnin15 and Nora Sandorfi16, 1Vanderbilt University Medical Center, Nashville, TN, 2McGovern Medical School, University of Texas, Houston, TX, 3Hospital for Special Surgery, New York, NY, 4Columbia University, New York, NY, 5Georgetown University School of Medicine, Washington, DC, 6Johns Hopkins Rheumatology, Baltimore, MD, 7Johns Hopkins Univerisity, Baltimore, MD, 8Northwestern University, Chicago, IL, 9Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 10Massachusetts General Hospital, Boston, MA, 11Stanford University, Stanford, CA, 12Medical University of South Carolina, Charleston, SC, 13George Washington University, Washington, DC, 14University of Utah, Salt Lake City, UT, 15Scleroderma Research Foundation, Brisbane, CA, 16University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Gastrointestinal tract (GIT) symptoms are common amongst systemic sclerosis (SSc) patients.1 The Scleroderma Clinical Trials Consortium University of California Los Angeles Gastrointestinal Tract Questionnaire…
  • Abstract Number: 0433 • ACR Convergence 2022

    Clustering of Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis – Using a Pre-processed Harmonised Dataset

    Karl Gisslander1, Arthur White2, Mårten Segelmark3, Mark Little2 and Aladdin Mohammad4, 1Lund University, Lund, Sweden, 2Trinity College, Dublin, Ireland, 3Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, 4Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden

    Background/Purpose: The sub-classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has been a long-standing debate. Unsupervised learning has previously been used for partitioning of phenotypic…
  • Abstract Number: 1679 • ACR Convergence 2022

    The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes

    Yukiko Kimura1, Sarah Ringold2, George Tomlinson3, Laura Schanberg4, Anne Dennos5, MaryEllen Riordan6, Vincent Del Gaizo7, Katherine Murphy8, Pamela Weiss9, Brian Feldman10, Mei Sing Ong11 and Marc Natter12, 1Hackensack Meridian Health, New York, NY, 2Janssen, Seattle, WA, 3University of Toronto, Toronto, ON, Canada, 4Duke University Medical Center, Durham, NC, 5Duke University, Durham, NC, 6Hackensack Meridian Health, Hackensack, NJ, 7CARRA, Inc, Washington, DC, 8CARRA, Inc, New Orleans, LA, 9Children's Hospital of Philadelphia, Glen Mills, PA, 10Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 11Harvard Pilgrim Institute, Boston, MA, 12Boston Children's Hospital, Boston, MA

    Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinically inactive disease (CID) in untreated polyarticular JIA…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology